PPARγ agonist and angiotensin II receptor antagonist ameliorate renal tubulointerstitial fibrosis

Journal of Korean Medical Science

Volumn 25, Issue 1, 2010, Pages 35-41

  Han, Jee Young ^a   Kim, Ye Ji ^a   Kim, Lucia ^a   Choi, Suk Jin ^a   Park, In Suh ^a   Kim, Joon Mee ^a   Chu, Young Chae ^a   Cha, Dae Ryong ^b  

^a Inha University Hospital   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Angiotensin; Fibrosis; Plasminogen activator inhibitor 1; PPAR gamma; Receptors; Transforming growth factor beta

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR; ANTIDIABETIC AGENT; DIFFERENTIATION ANTIGEN; MONOCYTE MACROPHAGE DIFFERENTIATION ANTIGEN; MONOCYTE-MACROPHAGE DIFFERENTIATION ANTIGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL; ARTICLE; C57BL MOUSE; DISEASE MODEL; DRUG ANTAGONISM; DRUG POTENTIATION; FIBROSIS; GENETICS; KIDNEY; MALE; METABOLISM; MOUSE; PATHOLOGY; URETER OBSTRUCTION;

ANIMALS; ANTIGENS, DIFFERENTIATION; DISEASE MODELS, ANIMAL; FIBROSIS; HYPOGLYCEMIC AGENTS; KIDNEY; MALE; MICE; MICE, INBRED C57BL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PPAR GAMMA; RECEPTORS, ANGIOTENSIN; SMAD2 PROTEIN; THIAZOLIDINEDIONES; TRANSFORMING GROWTH FACTOR BETA1; URETERAL OBSTRUCTION;

EID: 77949324227     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2010.25.1.35     Document Type: Article

References (28)

1. Guan Y, Zhang Y, Breyer MD. The role of PPARs in the transcription control of the cellular processes. Drug News Prospect 2002; 15: 147-54.
2. McCarthy KJ, Routh RE, Shaw W, Walsh K, Welbourne TC, Johnson JH. Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kiney Int 2000; 58: 2341-50.
3. Smith SA, Lister CA, Toseland CD, Buckingham RE. Rosiglitazone prevents the onset of hyperglycemia and proteinuria in the Zucker diabetic fatty rats. Daibetes Obes Metab 2000; 2: 363-72.
4. Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against non-diabetic glomerulosclerosis in rats. Kidney Int 2001; 59: 1899-910.
5. Ghosh SS, Gehr TW, Ghosh S, Fakhry I, Sica DA, Lyall V, Schoolwerth AC. PPARgamma ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase. Kidney Int 2003; 64: 52-62.
6. Routh RE, Johnson JH, McCarthy KJ. Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro. Kidney Int 2002; 61: 1365-76.
7. Guo B, Koya D, Isono M, Sugimoto T, Kashiwagi A, Haneda M. Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerulomesangial cells. Diabetes 2004; 53: 200-8.
8. Eddy AA. Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol 1994; 5: 1273-87.
9. Miyajima A, Chen J, Lawrence C, Ledbetter S, Soslow RA, Stern J, Jha S, Pigato J, Lemer ML, Poppas DP, Vaughan ED, Felsen D. Antibody to transforming growth factor-beta ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney Int 2000; 58: 2301-13.
10. Duymelinck C, Dauwe SE, De Greef KE, Ysebaert DK, Verpooten GA, De Broe ME. TIMP-1 gene expression and PAI-1 antigen after unilateral ureteral obstruction in adult male rat. Kidney Int 2000; 58: 1186-201.
11. Ma J, Nishimura H, Fogo A, Kon V, Inagami T, Ichikawa I. Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. Kidney Int 1998; 53: 937-44.
12. Bonegio RG, Fuhro R, Wang Z, Valeri CR, Andry C, Salant DJ, Lieberthal W. Rapamycin ameliorates proteinuria associated tubulointerstitial fibrosis inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005; 16: 2063-72.
13. Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 2001; 159: 1465-75.
14. Buckinham RE, Al-Barazanji KA, Toseland CD, Slaughter M, Connor SC, West A, Bond B, Turner NC, Clapham JC. Peroxisom proliferator-activated receptor gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabets 1998; 47: 1326-34.
15. Fujii M, Takemura R, Yamaguchi M, Hasegawa G, Shigeta H, Na kano K, Kondo M. Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats. Metabolism 1997; 46: 981-3.
16. Imano E, Kanda T, Nakatani Y, Nishida T, Arai K, Motomura M, Kajimoto Y, Yamasaki Y, Hori M. Effect of troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Diabetes Care 1998; 21: 2135-9.
17. Zafirious S, Stanners SR, Saad S, Polhill TS, Poronnik P, Pollock CA. Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts. J Am Soc Nephrol 2005; 16: 638-45.
18. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 2002; 283: F209-20.
19. Fogo AB. The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis 2000; 35: 179-88.
20. Brown NJ, Vaughan DE, Fogo AB. Aldosterone and PAI-1: implications for renal injury. J Nephrol 2002; 15: 230-5.
21. Panchapakesan U, Sumual S, Pollock CA, Chen X. PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. Am J Physiol Renal Physiol 2005; 289: F1153-8.
22. Li Y, Wen X, Spataro BC, Hu K, Dai C, Liu Y. Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists. J Am Soc Nephrol 2006; 17: 54-65.
23. Massague J, Chen YG. Controlling TGF-beta signaling. Genes Dev 2000; 14: 627-44.
24. Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol 2000; 15: 290-301.
25. Diamond JR. Macrophages and progressive renal disease in experimental hydronephrosis. Am J Kidney Dis 1995; 26: 133-40.
26. Ishidoya S, Morrissey J, McCracken R, Reyes A, Klahr S. Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 1995; 47: 1285-94.
27. Yao Q, Ayala ER, Qian JQ, Stenvinkel P, Axelsson J, Lindholm B. A combination of PPAR gamma agonist and an angiotensin receptor blocker attenuates proinflammatory signaling and stimulates expression of Smad7 in human peritoneal mesothelial cells. Clin Nephrol 2007; 68: 295-301.
28. Schmerbach K, Schefe JH, Krikov M, Mu_ller S, Villringer A, Kintscher U, Unger T, Thoene-Reineke C. Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia rat brain. Brain Res 2008; 7: 225-33.